Literature DB >> 27918720

What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.

Laureen Ribassin-Majed1, Sophie Marguet1, Anne W M Lee1, Wai Tong Ng1, Jun Ma1, Anthony T C Chan1, Pei-Yu Huang1, Guopei Zhu1, Daniel T T Chua1, Yong Chen1, Hai-Qiang Mai1, Dora L W Kwong1, Shie-Lee Cheah1, James Moon1, Yuk Tung1, Kwan-Hwa Chi1, George Fountzilas1, Jean Bourhis1, Jean Pierre Pignon1, Pierre Blanchard1.   

Abstract

Purpose The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial. The individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments. Methods All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixed- and random-effects frequentist network meta-analysis models were applied. Results The three treatments with the highest probability of benefit on overall survival (OS) were CRT-AC, followed by CRT and IC-CRT, with respective hazard ratios (HRs [95% CIs]) compared with RT alone of 0.65 (0.56 to 0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS, progression-free survival (PFS), locoregional control, and distant control (DC) were, respectively, 0.85 (0.68 to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and the best for DC. CRT never ranked first. HRs of CRT compared with IC-CRT for OS, PFS, locoregional control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55 (0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity. Conclusion The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points. The addition of IC to CRT achieved the highest effect on DC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27918720      PMCID: PMC5791836          DOI: 10.1200/JCO.2016.67.4119

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  44 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.

Authors:  Georgia Salanti; A E Ades; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2010-08-05       Impact factor: 6.437

3.  Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.

Authors:  Terence Tan; Wan-Teck Lim; Kam-Weng Fong; Shie-Lee Cheah; Yoke-Lim Soong; Mei-Kim Ang; Quan-Sing Ng; Daniel Tan; Whee-Sze Ong; Sze-Huey Tan; Connie Yip; Daniel Quah; Khee-Chee Soo; Joseph Wee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

4.  Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.

Authors:  D T Chua; J S Sham; D Choy; V Lorvidhaya; Y Sumitsawan; S Thongprasert; V Vootiprux; A Cheirsilpa; T Azhar; A H Reksodiputro
Journal:  Cancer       Date:  1998-12-01       Impact factor: 6.860

Review 5.  Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era.

Authors:  Anne W M Lee; Wai Tong Ng; Lucy L K Chan; Wai Man Hung; Connie C C Chan; Henry C K Sze; Oscar S H Chan; Amy T Y Chang; Rebecca M W Yeung
Journal:  Radiother Oncol       Date:  2014-03-11       Impact factor: 6.280

6.  A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Y P Chen; Z X Wang; L Chen; X Liu; L L Tang; Y P Mao; W F Li; A H Lin; Y Sun; J Ma
Journal:  Ann Oncol       Date:  2014-10-29       Impact factor: 32.976

7.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.

Authors:  Dora L W Kwong; Jonathan S T Sham; Gordon K H Au; Daniel T T Chua; Philip W K Kwong; Ashley C K Cheng; P M Wu; Martin W M Law; Carol C H Kwok; C C Yau; K Y Wan; Raymond T T Chan; Damon D K Choy
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

8.  The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials.

Authors:  Hongliang Yu; Dayong Gu; Xia He; Xianshu Gao; Xiuhua Bian
Journal:  Onco Targets Ther       Date:  2016-01-05       Impact factor: 4.147

9.  Ranking treatments in frequentist network meta-analysis works without resampling methods.

Authors:  Gerta Rücker; Guido Schwarzer
Journal:  BMC Med Res Methodol       Date:  2015-07-31       Impact factor: 4.615

10.  Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials.

Authors:  Yu-Pei Chen; Rui Guo; Na Liu; Xu Liu; Yan-Ping Mao; Ling-Long Tang; Guan-Qun Zhou; Ai-Hua Lin; Ying Sun; Jun Ma
Journal:  J Cancer       Date:  2015-07-17       Impact factor: 4.207

View more
  82 in total

1.  Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.

Authors:  Carlos Rodriguez-Galindo; Mark D Krailo; Matthew J Krasin; Li Huang; M Beth McCarville; John Hicks; Farzana Pashankar; Alberto S Pappo
Journal:  J Clin Oncol       Date:  2019-09-25       Impact factor: 44.544

Review 2.  The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Liang Peng; Jin-Qi Liu; Yu-Pei Chen; Jun Ma
Journal:  Br J Radiol       Date:  2019-05-24       Impact factor: 3.039

Review 3.  Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.

Authors:  Lucheng Fang; Licai Shi; Wen Wang; Tingting Hu; Xingwang Rao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-17       Impact factor: 2.503

4.  Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma.

Authors:  Yu-Hung Chen; Kai-Ping Chang; Sung-Chao Chu; Tzu-Chen Yen; Ling-Yi Wang; Joseph Tung-Chieh Chang; Cheng-Lung Hsu; Shu-Hang Ng; Shu-Hsin Liu; Sheng-Chieh Chan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-27       Impact factor: 9.236

Review 5.  Update in pediatric nasopharyngeal undifferentiated carcinoma.

Authors:  Line Claude; Emmanuel Jouglar; Loig Duverge; Daniel Orbach
Journal:  Br J Radiol       Date:  2019-07-31       Impact factor: 3.039

6.  Nodal grouping in nasopharyngeal carcinoma: prognostic significance, N classification, and a marker for the identification of candidates for induction chemotherapy.

Authors:  Yifei Liu; Shenghuan Chen; Annan Dong; Fei Ai; Tingting Quan; Chunyan Cui; Jian Zhou; Shaobo Liang; Jiamin Wang; Shunxin Wang; Ling Hua; Shuoyu Xu; Mingyuan Chen; Ying Sun; Haojiang Li; Lizhi Liu
Journal:  Eur Radiol       Date:  2019-12-06       Impact factor: 5.315

7.  A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma.

Authors:  Pu-Yun OuYang; Xiao-Min Zhang; Xing-Sheng Qiu; Zhi-Qiao Liu; Lixia Lu; Yuan-Hong Gao; Fang-Yun Xie
Journal:  Oncologist       Date:  2019-02-19

8.  Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.

Authors:  Gabriel Bandeira; Katia Rocha; Monize Lazar; Suzana Ezquina; Guilherme Yamamoto; Monica Varela; Vanessa Takahashi; Meire Aguena; Thomaz Gollop; Mayana Zatz; Maria Rita Passos-Bueno; Ana Krepischi; Oswaldo Keith Okamoto
Journal:  Breast Cancer       Date:  2020-09-28       Impact factor: 4.239

Review 9.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

10.  Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.

Authors:  Ying Lu; Dagui Chen; Jinhui Liang; Jianquan Gao; Zhanxiong Luo; Rensheng Wang; Wenqi Liu; Changjie Huang; Xuejian Ning; Meilian Liu; Haixin Huang
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.